UnitedHealth's Margin Collapse Has Further to Run

The medical cost ratio (MCR) inflection that began in mid-2023 was originally framed by management as a transitory normalisation after pandemic-era under-utilisation. That framing has not aged well. The 2024 MCR finished at roughly 85.5%, well above the 82-83% historical zone. The 2025 print pushed it higher, with management guiding to a stabilised level above 86%. Each 100 basis point of MCR pressure on a $300 billion-plus medical premium base is roughly $3 billion of operating income.

Layer in three other compounding factors. First, the V28 Medicare Advantage risk-adjustment phase-in is structurally compressing per-member revenue without a matching cost reset. The full cycle ends in 2026, meaning there is at least one more year of headline pressure baked in. Second, Optum Health's value-based care book grew faster than its pricing, which means the mix shift that historically lifted segment margins is now diluting them. Third, behavioural health and specialty utilisation, which exploded in late 2024, has not reverted to baseline.

Look at the income statement again. Gross profit fell from $89.4 billion in 2024 to $82.9 billion in 2025, despite a $47 billion revenue increase. That is not a cyclical accounting blip. That is a line-item indication that the cost base is growing faster than the price base. Historically, MCR-driven margin compression cycles in managed care have lasted 6-8 quarters from peak to trough. UNH is roughly four quarters into the current cycle. The pattern is clear: peak pain is still 2-4 quarters out, not behind.

The $1.6 billion Alegeus benefits-technology deal announced this month is being framed by management as a strategic capability play. Look, capability deals are fine. They are not the lever that fixes a structural cost trend. Operationally, UNH is at the mercy of the same medical inflation curve every other carrier is fighting. The acquisition pipeline is not a substitute for an MCR plan.

Managed care entered 2024 with a confident expectation. Pandemic-era under-utilisation had inflated reserves, and the 2023 normalisation appeared to be running its course. The base case across the sector, including UnitedHealth's own guidance, was that medical cost trend would settle in the 6-7% range by mid-2024 and revert to a 5-6% glidepath through 2025.

That expectation was wrong on every dimension. Behavioural health utilisation accelerated, not normalised. GLP-1 prescription growth blew through the modelling assumptions baked into 2024 pricing. Outpatient surgical volume, particularly in cardiology and orthopaedics, ran 200-300 basis points above the budgeted trend. Specialty pharmacy mix shifted toward higher-cost biologics faster than rebate negotiations could absorb. By Q3 2024, the cost trend was running closer to 9% on a same-membership basis. That is a 200-300 basis point miss, sustained for four quarters and counting.

The consensus narrative is now coalescing around a 2026 trough. The Risk Desk view is more sceptical. Cost trend pressure of this magnitude historically requires two complete pricing cycles to fully absorb, and Medicare Advantage pricing is a one-year reset. That mathematically means at least one more cycle of margin compression before the operating margin line stabilises, and the V28 phase-in compounds the timing problem.

Free cash flow has fallen for two consecutive years, from $25.7 billion in 2023 to $16.1 billion in 2025. That is a 37% reduction in cash generation against a backdrop where UNH's debt load grew from $67.4 billion to $78.4 billion and the share count remains flat. The cash conversion story that made this stock a defensive compounder has weakened materially.

Return on assets sits at roughly 4.0%, down from 8.2% in 2023. Operating margin sits at 4.2%, half the level of 2022. The dividend payout ratio, at $9.06 per share against a depressed EPS base of around $13.20, is now 68%. Historically, UNH has run a 30-40% payout ratio. The cushion is gone. Either earnings recover quickly (and the bull case rests on this) or the dividend grows below historical 14% pace from here. The data does not currently support the recovery thesis.

The $78.4 billion debt stack is not, by itself, a problem. UNH still generates enough cash to cover interest several times over. The issue is that interest costs at a 4.5%+ refinancing rate are absorbing a larger share of operating income than they have at any point in the past decade. That is a slow-acting headwind, not an acute one. It is, however, an additional drag the consensus model is not pricing aggressively enough.

Return on invested capital, the metric the Risk Desk weights most heavily for managed care, has dropped from 12% in 2022 to under 6% on a TTM basis. That is structurally below the cost of capital. A business that earns less than its cost of capital does not deserve a market multiple, full stop.

Optum was, for the better part of a decade, the structural answer to managed care's cost-trend volatility. Optum Rx generated double-digit operating margins. Optum Health, while messier, contributed segment-level operating income growth that comfortably outpaced the medical insurance side. The combined Optum operating income line peaked at $15.5 billion in 2023 and accounted for roughly 48% of UNH's total operating profit.

That picture has shifted materially. Optum Health's value-based care expansion, particularly through Change Healthcare integration aftermath and the LHC Group bolt-on, brought in revenue but at a per-member margin well below the legacy book. The 2025 segment operating margin for Optum Health compressed from 7.8% to 5.4% on rough estimates from the disclosed segment data. Optum Rx remains the bright spot, but at low-double-digit margins it cannot offset the headline medical cost pressure on its own.

The competitive read across the carrier peer set tells the same story. Humana's MA exposure was hit harder, and the multiple compression there has been brutal. Elevance has held up better thanks to a more diversified mix, but its operating margin trajectory is also negative year on year. Centene's Q1 print, often used as a positive sector data-point, was lifted by Medicaid premium re-pricing that does not flow to UNH's product mix. The pattern is consistent: nobody in this sector has cracked the cost trend yet. UNH, with the highest MA exposure, sits at the centre of the pressure.

Run the bull case backward. Forward 2026 EPS of $17.50, the rough Street consensus, requires operating income to recover from the 2025 base of $19.0 billion to roughly $26-27 billion. That is a 36-42% rebound year-on-year. Looking at every prior managed care drawdown going back to the 1990s, the largest single-year operating income recovery from a margin-compression trough was 28%. The current consensus is therefore baking in a recovery that has no historical precedent in the sector.

For that to actually happen, three things have to break favourably and simultaneously. The medical cost trend has to fall from 9% to 6-7% inside twelve months. Premium pricing for the 2026 MA bid year, which is already filed, has to capture more cost than the V28 risk-adjustment phase-in extracts. And Optum Health margins have to bottom in 2026 rather than continuing to slide. The base rate on three favourable simultaneous trend breaks in a managed care cycle is, generously, 15-20%.

This is the biggest execution risk in the consensus thesis. The Risk Desk model anchors on a more sober 2026 EPS of $14.00, which assumes operating income recovers to $22 billion (a 16% rebound), MCR remains in the 85-86% zone, and Optum Health margin holds at the 2025 level rather than recovering. At $14.00 of EPS and the prevailing 19.6x multiple, fair value lands at $274. That is the maths that drives the bearish stance.